Drug Approval | June 24, 2022
ANI Pharmaceuticals gets FDA approval of Clorazepate Dipotassium Tablets USP
ANI’s Clorazepate Dipotassium Tablets are the generic version of the Reference Listed Drug (RLD) Tranxene.
ANI’s Clorazepate Dipotassium Tablets are the generic version of the Reference Listed Drug (RLD) Tranxene.
It´s the first trial to demonstrate the benefits of dual pathway inhibition
Silo enters into commercial evaluation license agreement for next generation liposomes
Alliances with CVS Health and Javara further embed clinical research into the community healthcare setting, expanding access to patient populations across the U.S to increase diversity in clinical trials
Indira IVF has established technological supremacy as the key differentiator, delivering industry leading success rate
Expanding diagnostics footprint in East India
If approved, Tafinlar + Mekinist may offer a potential new standard-of-care for pediatric patients with this brain cancer
The company has posted net profit of Rs.165.66 crores for the Financial Year ended March 31, 2022
Active pharmaceutical ingredients revenue for the quarter was at Rs 913 crore
The information center has been established with the aim of providing Fortis Healthcare’s world-class healthcare services accessible to the people of Tirupati.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
